MULLERIAN-INHIBITING SUBSTANCE IS PRESENT IN EMBRYONIC TESTES OF DOGS WITH PERSISTENT MULLERIAN DUCT SYNDROME

被引:27
|
作者
MEYERSWALLEN, VN
LEE, MM
MANGANARO, TF
KURODA, T
MACLAUGHLIN, D
DONAHOE, PK
机构
[1] CORNELL UNIV,COLL VET MED,JA BAKER INST,ITHACA,NY 14853
[2] CORNELL UNIV,COLL VET MED,DEPT CLIN SCI,ITHACA,NY 14853
[3] MASSACHUSETTS GEN HOSP,DEPT PEDIAT SURG,BOSTON,MA 02114
[4] MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114
关键词
D O I
10.1095/biolreprod48.6.1410
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Mullerian Inhibiting Substance (MIS) causes regression of the Mullerian ducts during a critical period in embryonic development in male mammals. In Persistent Mullerian Duct Syndrome (PMDS), an autosomal recessive trait in humans and dogs, the Mullerian ducts fail to regress in otherwise normal males. Previously we reported that PMDS-affected dogs produce bioactive testicular MIS postnatally. The purpose of the present study was to determine whether PMDS-affected canine embryos appropriately express MIS mRNA and protein during the critical period for Mullerian duct regression. Homozygous (PMDS-affected) and normal canine embryos were removed from timed pregnancies. Gonadal sex and the degree of Mullerian duct regression were determined from histologic sections. Positive immunohistochemical staining for MIS was found in testis sections of PMDS-affected and normal male embryos. A 1.8-kb MIS mRNA transcript was detected in testes of PMDS-affected males and normal male embryos and neonates. Furthermore, equal amounts of MIS mRNA transcript were detected in testes of PMDS-affected embryos and normal male littermates during the critical period for Mullerian duct regression. These data support a hypothesis of target organ resistance, such as an abnormality in the putative MIS receptor, as the etiology of the defect in this dog model.
引用
收藏
页码:1410 / 1418
页数:9
相关论文
共 50 条
  • [31] QUANTITATIVE CHANGE IN FIBRONECTIN IN CULTURED MULLERIAN MESENCHYMAL CELLS IN RESPONSE TO DIETHYLSTILBESTROL AND MULLERIAN-INHIBITING SUBSTANCE
    TENG, CS
    DEVELOPMENTAL BIOLOGY, 1990, 140 (01) : 1 - 7
  • [32] SYNERGISTIC EFFECTS OF INHIBINS AND MULLERIAN-INHIBITING SUBSTANCE ON TESTICULAR TUMORIGENESIS
    MATZUK, MM
    FINEGOLD, MJ
    MISHINA, Y
    BRADLEY, A
    BEHRINGER, RR
    MOLECULAR ENDOCRINOLOGY, 1995, 9 (10) : 1337 - 1345
  • [33] Mullerian-inhibiting substance regulates androgen synthesis at the transcriptional level
    Teixeira, J
    Fynn-Thompson, E
    Payne, AH
    Donahoe, PK
    ENDOCRINOLOGY, 1999, 140 (10) : 4732 - 4738
  • [34] MULLERIAN INHIBITING SUBSTANCE IN HUMAN TESTES AFTER BIRTH
    DONAHOE, PK
    ITO, Y
    MORIKAWA, Y
    HENDREN, WH
    JOURNAL OF PEDIATRIC SURGERY, 1977, 12 (03) : 323 - 330
  • [35] GERM-CELL DEVELOPMENT IN NEONATAL MOUSE TESTES IN-VITRO REQUIRES MULLERIAN-INHIBITING SUBSTANCE
    ZHOU, BY
    WATTS, LM
    HUTSON, JM
    JOURNAL OF UROLOGY, 1993, 150 (02): : 613 - 616
  • [36] INTERSPECIFIC CHARACTER OF MULLERIAN-INHIBITING SUBSTANCE - ACTION OF HUMAN FETAL TESTIS, OVARY AND ADRENAL ON FETAL RAT MULLERIAN DUCT IN ORGAN CULTURE
    JOSSO, N
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1971, 32 (03): : 404 - +
  • [37] MULLERIAN-INHIBITING SUBSTANCE - NEW PERSPECTIVES AND FUTURE-DIRECTIONS
    CATLIN, EA
    MACLAUGHLIN, DT
    DONAHOE, PK
    MICROSCOPY RESEARCH AND TECHNIQUE, 1993, 25 (02) : 121 - 133
  • [38] Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics
    La Marca, A
    Orvieto, R
    Giulini, S
    Jasonni, VM
    Volpe, A
    De Leo, V
    FERTILITY AND STERILITY, 2004, 82 (04) : 970 - 972
  • [39] Persistent Mullerian duct syndrome: an update
    Picard, Jean-Yves
    Josso, Nathalie
    REPRODUCTION FERTILITY AND DEVELOPMENT, 2019, 31 (07) : 1240 - 1245
  • [40] Persistent mullerian duct syndrome: How to deal with the mullerian duct remnants - a review
    Manjunath, B. G.
    Shenoy, Vasanth G.
    Raj, Preetham
    INDIAN JOURNAL OF SURGERY, 2010, 72 (01) : 20 - 23